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The trial ALL-BFM 95 for treatment of
childhood acute lymphoblastic leukemia
was designed to reduce acute and long-
term toxicity in selected patient groups
with favorable prognosis and to improve
outcome in poor-risk groups by treatment
intensification. These aims were pursued
through a stratification strategy using
white blood cell count, age, immunophe-
notype, treatment response, and unfavor-
able genetic aberrations providing an ex-
cellent discrimination of risk groups.
Estimated 6-year event-free survival (6y-
pEFS) for all 2169 patients was 79.6%
( 0.9%). The large standard-risk (SR)
group (35% of patients) achieved an excel-
lent 6y-EFS of 89.5% ( 1.1%) despite
significant reduction of anthracyclines. In
the medium-risk (MR) group (53% of pa-
tients), 6y-pEFS was 79.7% ( 1.2%); no
improvement was accomplished by the
randomized use of additional intermedi-
ate-dose cytarabine after consolidation.
Omission of preventive cranial irradiation
in non–T-ALL MR patients was possible
without significant reduction of EFS, al-
though the incidence of central nervous
system relapses increased. In the high-
risk (HR) group (12% of patients), intensi-
fication of consolidation/reinduction treat-
ment led to considerable improvement
over the previous ALL-BFM trials yielding
a 6y-pEFS of 49.2% ( 3.2%). Compared
without previous trial ALL-BFM 90, consis-
tently favorable results in non-HR pa-
tients were achieved with significant treat-
ment reduction in the majority of these
patients. (Blood. 2008;111:4477-4489)
© 2008 by The American Society of Hematology
Introduction
Impressive improvements of survival rates in pediatric acute
lymphoblastic leukemia (ALL) have been achieved during the last
decades.1-21 Today, a long-term cure can be attained for approxi-
mately 75% of patients. The identification of biologic and clinical
prognostic factors allowed the definition of patient subgroups with
distinct relapse risks and the realization of risk-adapted treatment
strategies.
In ALL-Berlin-Frankfurt-Mu¨nster (BFM) trials, the so-called
prednisone response (PR, for definition see “Response and relapse
criteria”) evolved as one of the strongest prognostic factors.22,23
Patients with “prednisone good-response” (PGR) comprised 90%
of all patients with a cure rate of more than 80%, whereas patients
with inadequate PR (“prednisone poor-response,” PPR) had an
unfavorable outcome with a probability of event-free survival
(pEFS) of less than 50%. Thus, a small but relevant target group for
treatment modification was clearly identified.
Because of the excellent outcome of a large patient subset,
treatment toxicity had gained in importance. In consequence, a
major focus of study ALL-BFM 90, the study immediately before
ALL-BFM 95, was the reduction of treatment in favorable patient
groups to reduce acute and long-term toxicity.15 Despite the 25%
anthracycline dose reduction in induction, a significantly lower
relapse rate could be achieved in the medium-risk group, most
likely because of a more condensed application of induction
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therapy. Enabled by the introduction of high-dose methotrexate
(HD-MTX), presymptomatic cranial radiotherapy (pCRT) was
eliminated in low-risk ALL and stepwise reduced to 12 Gy in
medium- and high-risk ALL.15,23
After introduction of the PR as stratification criterion, the
formerly used BFM risk factor (BFM-RF), an estimator of the
initial leukemic cell mass, turned out to be an insufficient parame-
ter to separate different risk groups within PGR patients.15 There-
fore, a new stratification strategy was introduced in trial ALL-BFM
95, which used age, white blood cell count (WBC) at diagnosis, and
immunophenotype in addition to PR, response to induction treat-
ment, and the unfavorable translocations t(9;22) and t(4;11). This
enabled a better separation of subgroups with distinct relapse risks:
in trial ALL-BFM 90, stratification by the new criteria would have
resulted in a large “standard-risk” (SR) group of approximately
35% of all patients with a pEFS of approximately 90%, a
“medium-risk” (MR) group comprising approximately 50% of the
patients with a pEFS of 80%, and a “high-risk” (HR) group with a
pEFS of less than 50%.
Subsequent to trial ALL-BFM 90, the new trial ALL-BFM 95
aimed at further reduction of treatment burden while improving
outcome in selected subgroups. Objectives of trial ALL-BFM 95
were (1) reduction of the daunorubicin dose in induction treatment
by 50% in the SR group; (2) the extension of the maintenance
therapy by 12 months in SR boys to prevent the late relapses
observed in this patient group; (3) randomized intensification of the
extracompartment/consolidation phase with intermediate-dose (ID)
cytarabine in addition to high-dose methotrexate in the MR group;
(4) omission of pCRT in all MR patients with non-T-ALL; and
(5) modification of consolidation/reinduction in HR patients by
intensification in the block elements and reintroduction of protocol
II. In addition, intensification of maintenance therapy by pulses of
dexamethasone and vincristine was evaluated in the MR group in a
randomized intergroup trial of the International BFM Study Group,
demonstrating no benefit from the intensification.24 The use of
allogeneic stem cell transplantation (alloSCT) was not a primary
study objective but has been analyzed in detail and published
earlier indicating a benefit from alloSCT primarily for patients with
T-ALL.25,26
Methods
Patients
From April 1, 1995, until June 30, 2000, a total of 2283 patients younger
than 18 years with ALL were enrolled into the trial ALL-BFM 95. Patients
were treated in 82 participating study centers in Austria, Switzerland, and
Germany. Randomization of protocol M versus MCA in risk group MR
(Figure 1) started on October 1, 1995. Informed consent was obtained from
the guardians of each patient in accordance with the Declaration of
Helsinki. The trial was approved by the ethical committee of the principal
investigator’s institution.
The median follow-up period for the analyzed patients was 7.2 years.
Thirty-seven patients were considered lost to follow-up after a median
follow-up time of 3.0 years.
Diagnosis
The diagnosis of ALL was established if at least 25% lymphoblasts were
present in the bone marrow (BM). BM and peripheral blood (PB) smears as
well as cerebrospinal fluid (CSF) cytospin preparations were reviewed in
the study center.
Central nervous system (CNS) involvement was diagnosed if more than
5 cells/L were counted in CSF and lymphoblasts were identified or if
intracerebral infiltrates were detected on cranial computed tomography
(CNS3). If blasts were identified in CSF cytospin preparations although
CSF cell count was less than or equal to 5 cells/L, CNS status was
classified as CNS2; in the case of traumatic lumbar puncture with
identification of blasts, CNS status was categorized as TLP, and as TLP
if no blasts were identified.27
Immunophenotyping, DNA index, and cytogenetic and
molecular genetic analysis
Immunophenotyping, determination of cellular DNA content using flow
cytometry, and definition of DNA index was performed as previously
described.28,29 Cytogenetic studies were carried out using standard tech-
niques.30 RT-PCR-based screening for BCR/ABL and MLL/AF431,32 was
performed since the start of study; screening for TEL/AML133 was initiated
in May 1996.
Response and relapse criteria
PR was determined after 7 days of monotherapy with prednisone and one
intrathecal dose of methotrexate on day 1 and was centrally reviewed in the
study center. The presence of 1  109 blasts/L or more in PB on day 8 was
defined as PPR, fewer than 1  109 blasts/L as PGR.22 BM response was
evaluated in aspiration smears on day 33 of induction treatment. Complete
remission (CR) was defined as less than 5% blasts in the regenerating BM,
the absence of leukemic blasts in blood and CSF, and no evidence of
localized disease. Failure to achieve CR after induction was not considered
an event. Resistance to therapy (nonresponse) was defined as not having
achieved CR by the start of the fourth pulsatile high-dose block. Relapse
was defined as recurrence of 25% or more lymphoblasts in BM or localized
leukemic infiltrates at any site.
Stratification
Patients were stratified into 3 risk groups according to the following
criteria:
HR: PPR, and/or no CR on day 33, and/or evidence of t(9;22) (or
BCR/ABL), and/or evidence of t(4;11) (or MLL/AF4).
MR: No HR criteria, and initial WBC 20 109/L or more and/or age at
diagnosis less than 1 or 6 years or older, and/or T-ALL.
SR: No HR criteria, and initial WBC less than 20  109/L, and age at
diagnosis between 1 and 6 years, and no T-ALL.
CNS status was no stratification criterion.
Treatment
The treatment strategy is shown in Figure 1, and the details of treatment
elements are provided in Table 1. In SR patients, the number of daunorubi-
cin applications in induction was halved to 2 doses of 30 mg/m2 (protocol
I). In protocol M, HD-MTX at 5 g/m2 per 24 hours with late leucovorin
rescue was administered as described before.15
All HR patients received prophylactic granulocyte colony-stimulating
factor after each high-dose block.34 alloSCT was recommended for a subset
of HR patients if a matched sibling donor was available. Eligibility criteria
for alloSCT have been published before.25,26
Escherichia coli L-asparaginase from Medac (Wedel, Germany) was
used as first-line asparaginase preparation. In protocol I, dose was reduced
at 5000 IU/m2 because of the higher activity and toxicity compared with the
formerly applied preparation (Crasnitin).35,36 In case of allergic reactions,
Erwinia L-asparaginase (ERWINASE; Speywood, London, United King-
dom) or PEG-asparaginase (ONCASPAR, Medac) were recommended as a
substitute.
T-ALL and HR patients 1 year of age or older received pCRT with
12 Gy, scheduled after the end of reinduction (Figure 1). CNS3 patients
2 years of age or older received 18 Gy therapeutic CRT (tCRT) (12 Gy if
age was 2 years) and 2 additional intrathecal MTX doses in protocols I and
II each and if qualified for HR, one additional intrathecal triple drug
application in each HR-2 course. CNS2 or TLP patients received
2 additional intrathecal MTX doses in protocol I.
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Maintenance therapy with daily 6-mercaptopurine and weekly metho-
trexate was adjusted according to WBC (target range, 2 to 3 109/L).
Two randomizations were performed in the MR branch. The standard
protocol M (6-mercaptopurine and 4 cycles HD-MTX) was randomized
against the experimental arm protocol MCA, in which ID-cytarabine
(200 mg/m2 per 24 hours) was infused subsequently to each HD-MTX
infusion. The second randomization provided 6 pulses with dexamethasone
and vincristine applied every 10 weeks in addition to the standard
maintenance treatment and was performed within the framework of an
international collaboration.24
Historical control group
To evaluate the impact of treatment modifications that were not tested
through randomization, patients were retrospectively compared with the
matching subsets of patients from the previous trial ALL-BFM 90.15 Risk
stratification and treatment in ALL-BFM 90 have been described before15;
differences to ALL-BFM 95 are summarized in Table 2. For historical
comparison of the matching subgroups among the non-HR patients, patients
of ALL-BFM 90 were reclassified by the ALL-BFM 95 risk criteria
(“SR-95,” “MR-95”) and vice versa ALL-BFM 95 patients by the ALL-
BFM 90 risk criteria (“SR-90,” “MR-90”). The reclassification led to an
extensive redistribution of patients. Of the reclassified “SR-95” patients
from ALL-BFM 90, who constituted the historical control group for the
analysis of the impact of the daunorubicin reduction in the SR group in
ALL-BFM 95, 52% were treated in risk group “MR-90.” For evaluating the
omission of pCRT, ALL-BFM 90 patients of risk group “MR-90” 1 year of
age or older with pB-ALL and without initial CNS involvement served as
historical control group. In the corresponding group from ALL-BFM 95
which did not receive pCRT, 36% were treated in risk group “SR-95.”
Treatment in SR and MR in trial ALL-BFM 90 was basically comparable. It
differed in the indication for cranial irradiation and in the additional
asparaginase in protocol M given in the context of the randomized question
in the MR group in ALL-BFM 90 (Table 2). No significant impact on
outcome has been shown with respect to the additional asparaginase.15
Statistical analysis
EFS was defined as the time from diagnosis to the date of last follow-up in
complete remission or first event. Events were resistance to therapy
(nonresponse), relapse, secondary neoplasm (SN) or death from any cause.
Failure to achieve remission due to early death or nonresponse was
considered as events at time 0. Survival was defined as the time of diagnosis
to death from any cause or last follow-up. For analysis of randomized
patient subsets, disease-free survival (DFS) was calculated from time of
randomization to the first event or the last follow-up date. Patients lost to
follow-up were censored at the last contact. The Kaplan-Meier method was
used to estimate survival rates37; differences were compared with the
Figure 1. Treatment outline ALL-BFM 95. Details of treatment elements are listed in Table 1. Results of the randomization R2 and data on stem cell transplantation have been
published before.24-26 Dose of presymptomatic cranial radiotherapy was 12 Gy for patients aged 1 year or older. Therapeutic irradiation dose for patients with initial involvement
of the central nervous system was 12 Gy for patients 1 to 2 years and 18 Gy for patients more than 2 years of age. Infants younger than 1 year were neither preventively nor
therapeutically irradiated. SR indicates standard risk; MR, medium risk; HR, high risk; PDN, prednisone; VCR, vincristine; DNR, daunorubicin; ASP, E coli L-asparaginase;
MTX, methotrexate; 6-MP, 6-mercaptopurine; ARA-C, cytarabine; CPM, cyclophosphamide; DXM, dexamethasone; DOX, doxorubicin; 6-TG, 6-thioguanine; HD, high dose;
ID, intermediate dose; IT, intrathecal; TIT, triple intrathecal therapy; G-CSF, granulocyte colony-stimulating factor; MT, maintenance therapy; SCT, stem cell transplantation;
pCRT, presymptomatic cranial radiotherapy.
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2-sided log-rank test.38 Cox proportional hazards model was used for
univariate and multivariate analyses.39 Cumulative incidence (CI) functions
for competing events were constructed by the method of Kalbfleisch and
Prentice40 and were compared with the Gray test.41 Comparison of
randomized groups was performed as intent-to-treat and per-protocol
analysis. Differences in the distribution of individual parameters among
patient subsets were analyzed using the 2 test for categorized variables and
the Mann-Whitney U test for continuous variables.
Table 1. Treatment protocol
Treatment element/drug Single or daily dose Days of application per elementa
Induction/consolidation, protocol I
Phase A
Prednisone (PO) 60 mg/m2 per day 1-28fg
Vincristine (IV) 1.5 mg/m2 per dose (max 2 mg) 8, 15, 22, 29
Daunorubicin (PI over 1 hour) 30 mg/m2 per dose 8, 15, 22,h 29 h
L-asparaginase (PI over 1 hour) 5000 IU/m2 per dose 12, 15, 18, 21, 24, 27, 30,f 33f
Methotrexate (IT) 12 mg/dosei 1, 12, 33j
Phase B (only SR/MR)
Cyclophosphamide (PI over 1 hour) 1000 mg/m2 per dose 36, 64
Cytarabine (IV) 75 mg/m2 per dose 38-41, 45-48, 52-55, 59-62
6-mercaptopurine (PO) 60 mg/m2 per day 36-63
Methotrexate (IT) 12 mg/dosei 45, 59
Extracompartment therapy (only SR/MR)
Protocol M
6-mercaptopurine (PO) 25 mg/m2 per day 1-56
Methotrexate (PI over 24 hours)b 5000 mg/m2 per dose 8, 22, 36, 50
Methotrexate (IT) 12 mg/dosei 8, 22, 36, 50
Protocol MCA (only MR patients randomized into MR-2)
6-mercaptopurine (PO) 25 mg/m2 per day 1-56
Methotrexate (PI over 24 hours)b 5000 mg/m2 per dose 8, 22, 36, 50
Methotrexate (IT) 12 mg/dosei 8, 22, 36, 50
Cytarabine (PI over 24 hours) 200 mg/m2 per dose 9, 23, 37, 51
Intensive consolidation (only HR) (HR-1/HR-2/HR-3) 2
Element HR-1c
Dexamethasone (PO) 20 mg/m2 per day 1-5
Vincristine (IV) 1.5 mg/m2 (max 2 mg) 1,k 6k
Methotrexate (PI over 24 hours)b 5000 mg/m2 per dose 1
Cyclophosphamide (PI over 1 hour) 200 mg/m2 per dose 2-4 (5 doses, 12-hour intervals)
Cytarabine (PI over 3 hours) 2 g/m2 per dose 5 (2 doses, 12 h interval)
L-asparaginase (PI over 6 hours) 25 000 IU/m2 per dose 6
Methotrexate/cytarabine/prednisolone (IT) 12/30/10 mg/dosei 1
Element HR-2c
Dexamethasone (PO) 20 mg/m2 per day 1-5
Vindesine (IV) 3 mg/m2 per dose (max 5 mg) 1, 6
Methotrexate (PI over 24 hours)b 5000 mg/m2 per dose 1
Ifosfamide (PI over 1 hour) 800 mg/m2 per dose 2-4 (5 doses, 12-hour intervals)
Daunorubicin (PI over 24 hours) 30 mg/m2 per dose 5
L-asparaginase (PI over 6 hours) 25 000 IU/m2 per dose 6
Methotrexate/cytarabine/prednisolone (IT) 12/30/10 mg/dosei 1l
Element HR-3c
Dexamethasone (PO) 20 mg/m2 per day 1-5
Cytarabine (PI over 3 hours) 2 g/m2 per dose 1-2 (4 doses, 12-hour intervals)
Etoposide (PI over 1 hour) 100 mg/m2 per dose 3-5 (5 doses, 12-hour intervals)
L-asparaginase (PI over 6 hours) 25 000 IU/m2 per dose 6
Methotrexate/cytarabine/prednisolone (IT) 12/30/10 mg/dosei 5
PO indicates orally; IV, intravenous push; PI, intravenous infusion; IT, intrathecally.
aAdjustments of time schedule were allowed if clinical condition and bone marrow recovery were inadequate (according to protocol guidelines).
bA loading dose of 10% was infused over 30 minutes, the remaining 90% over 23.5 hours. Leucovorin rescue was given at hours 42, 48, and 54 (each 15 mg/m2). Increased
leucovorin doses was given, when MTX levels at hour 42 or later were 1.0 mol/L. If the MTX level at hour 54 was 0.25 mol/L, rescue was continued at 6-hour intervals
until MTX levels were0.25 mol/L.
cEach HR block was given twice (Figure 1).
dMaintenance was given from end of intensive chemotherapy until 104 weeks after diagnosis, for boys in SR until 156 weeks.
eSix pulses were given every 10 weeks.
fIn HR, protocol I/phase A was given with only 21 days of prednisone and 6 doses of L-asparaginase.
gSteroids were tapered over 9 days.
hIn SR, the daunorubicin doses on days 22 and 29 were omitted.
iDoses were adjusted for children younger than 3 years.
jThe day 33 IT methotrexate dose was scheduled on day 27 in HR patients. Patients with CNS status CNS2, TLP, or CNS3 received additional IT methotrexate on days
18 and 27 (SR or MR) or on day 18 (HR).
kVincristine was omitted in the first HR-1 course.
lPatients with CNS status CNS 3 received additional IT methotrexate on day 5.
mPatients with CNS status CNS 3 received additional IT methotrexate on days 1 and 18.
nDoses were adjusted to WBC (target range, 2000-3000/L).
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At the end of protocol I, MR patients were randomly assigned to either
receive additional cytarabine or not in protocol M. The sample size was
derived based on the primary endpoint of DFS. According to the results of
the preceded studies, the probability of long-term DFS of MR patients
treated with protocol M was estimated to be 73%. To detect an increase of
9% (8%, 7%), a total of 680 (872, 1154) patients were required to be
randomized (alpha 	 0.05, beta 	 0.2).42
Statistical analyses were conducted using the SAS program (SAS-PC,
version 9.1; SAS Institute, Cary, NC).
All patient data were updated in June 2006.
Table 1. Treatment protocol (continued)
Treatment element/drug Single or daily dose Days of application per elementa
Reinduction, protocol II
Phase A
Dexamethasone (PO) 60 mg/m2 per day 1-21g
Vincristine (IV) 1.5 mg/m2 per dose (max 2 mg) 8, 15, 22, 29
Doxorubicin (PI over 1 hour) 30 mg/m2 per dose 8, 15, 22, 29
L-asparaginase (PI over 1 hour) 10 000 IU/m2 per dose 8, 11, 15, 18
Phase B
Cyclophosphamide (PI over 1 hour) 1000 mg/m2 per dose 36
Cytarabine (IV) 75 mg/m2 per dose 38-41, 45-48
6-thioguanine (PO) 60 mg/m2 per day 36-49
Methotrexate (IT) 12 mg/dosei 45, 59m
Maintenance therapyd
Methotrexate (PO) 20 mg/m2 per dosen Once a week
6-mercaptopurine (PO) 50 mg/m2 per dayn Daily
Only MR patients randomized into MR-B
Methotrexate (PO) 20 mg/m2 per dosen Once a week
6-mercaptopurine (PO) 50 mg/m2 per dayn Daily
Dexamethasone (PO)e 6 mg/m2 per day 1-7 per pulse
Vincristine (IV)e 1.5 mg/m2 per dose (max 2 mg) 1, 7 per pulse
PO indicates orally; IV, intravenous push; PI, intravenous infusion; IT, intrathecally.
aAdjustments of time schedule were allowed if clinical condition and bone marrow recovery were inadequate (according to protocol guidelines).
bA loading dose of 10% was infused over 30 minutes, the remaining 90% over 23.5 hours. Leucovorin rescue was given at hours 42, 48, and 54 (each 15 mg/m2). Increased
leucovorin doses was given, when MTX levels at hour 42 or later were 1.0 mol/L. If the MTX level at hour 54 was 0.25 mol/L, rescue was continued at 6-hour intervals
until MTX levels were0.25 mol/L.
cEach HR block was given twice (Figure 1).
dMaintenance was given from end of intensive chemotherapy until 104 weeks after diagnosis, for boys in SR until 156 weeks.
eSix pulses were given every 10 weeks.
fIn HR, protocol I/phase A was given with only 21 days of prednisone and 6 doses of L-asparaginase.
gSteroids were tapered over 9 days.
hIn SR, the daunorubicin doses on days 22 and 29 were omitted.
iDoses were adjusted for children younger than 3 years.
jThe day 33 IT methotrexate dose was scheduled on day 27 in HR patients. Patients with CNS status CNS2, TLP, or CNS3 received additional IT methotrexate on days
18 and 27 (SR or MR) or on day 18 (HR).
kVincristine was omitted in the first HR-1 course.
lPatients with CNS status CNS 3 received additional IT methotrexate on day 5.
mPatients with CNS status CNS 3 received additional IT methotrexate on days 1 and 18.
nDoses were adjusted to WBC (target range, 2000-3000/L).
Table 2. Comparison of study ALL-BFM 90 and 95: differences in risk groups definitions and treatment
ALL-BFM 90 ALL-BFM 95
All risk groups
Asparaginase preparation Crasnitin L-asparaginase Medac
Asparaginase dosage in protocol I 10 000 IU/m2 per dose 5000 IU/m2 per dose
SR*
SR criteria No HR-90 criteria and BFM-RF 
0.8 and no
T-ALL and CNS-negative
No HR-95 criteria and age 1 to 
6 years and WBC

20  109/L and no T-ALL
Chemotherapy protocol IA 4 doses daunorubicin 2 doses daunorubicin
Duration of maintenance for boys 24 months from diagnosis 36 months from diagnosis
MR*
MR criteria No HR-90 criteria and BFM-RF 0.8 and/or
T-ALL and/or CNS-positive
No HR-95 criteria and age 
1 or6 years and/or WBC
20  109/L and/or T-ALL
Presymptomatic cranial irradiation 12 Gy 0 Gy (T-ALL: 12 Gy)
Randomization protocol M  asparaginase  cytarabine
Randomization maintenance  Vincristine/dexamethasone pulses
HR*
HR criteria PPR and/or no CR d33 and/or t(9;22) (or
BCR/ABL)
PPR and/or no CR d33 and/or t(9;22) (or BCR/ABL) or t(4;11)
(or MLL/AF4)
Consolidation/reinduction 9 HR courses 6 HR courses protocol II
*Risk groups as defined in ALL-BFM 90 and 95, respectively.
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Results
Patients’ characteristics
Of the 2283 patients enrolled in ALL-BFM 95, 39 patients were
excluded because of participation in pilot trials for feasibility of
protocol MCA (n 	 20) and for the infant ALL trial INTERFANT
9943 (n 	 19). Seventy-five patients were not eligible according to
the protocol criteria for the following reasons: significant pretreat-
ment (n 	 44), ALL was a SN (n 	 9), major medical ailment
preventing protocol therapy (patients with Down syndrome were
only excluded if premorbidity prevented protocol therapy; n 	 4),
lack of essential data for establishing the diagnosis (n 	 5),
incorrect diagnosis (n 	 3), treatment in a different protocol
(n 	 2), death before start of protocol treatment or treatment
in a nonparticipating center (n 	 2), and age at diagnosis older
than 18 years (n 	 6). Eventually, 2169 patients were evaluable for
this study.
Patient characteristics and early treatment response of the total
evaluable population and according to risk groups are summarized
in Table 3. Basic characteristics (sex, age, WBC, immunopheno-
type) were comparable in trials ALL-BFM 90 and 95 (Table S1,
available on the Blood website; see the Supplemental Materials
link at the top of the online article).
Event-free survival
The pEFS at 6 years (6y-pEFS  SE) for all 2283 study patients of
ALL-BFM 95 was 78.6% ( 0.9%); probability of survival at 6
years (6y-SUR  SE) was 86.3% ( 0.6%). For the 2169 evalu-
able patients, 6y-pEFS was 79.6% ( 0.9%; Figure 2); 6y-SUR
was 87.0% ( 0.7%). CR was achieved by 99.1% of evaluable
patients. In comparison to the previous trial ALL-BFM 90, there
was a slight improvement of 6y-pEFS (P 	 .062; Figure 2) and
6y-SUR (6y-SUR ALL-BFM 90: 84.8%  0.8%, P 	 .044).
Stratification by the ALL-BFM 95 risk criteria resulted in
distinct groups with 6y-pEFS of 89.5% ( 1.1%) for SR, 79.7%
( 1.2%) for MR, and 49.2% ( 3.2%) for HR (Figure 3).
Events
Remission failures. Twenty patients failed to achieve remission
because of early death or resistant disease. Sixteen patients died
during the 5-week induction (protocol IA); 5 of them died of
leukemia-associated complications; in 11 patients, death was
suspected to be treatment-related (Table 4). Among 49 patients who
were not in remission by protocol day 33, 45 finally reached CR by
the start of fourth HR course. Four patients had not achieved CR by
this time point (nonresponse).
Deaths in CR. Forty-six patients (2.1%) died after achieve-
ment of CR because of treatment complications. Incidence was
highest in the HR group (8.7%, 22 deaths, 13 of them resulting
from alloSCT-related complications). Twenty-four patients with
death in CR were treated in SR and MR. Nine of them died in
protocol I, 11 in protocol II, and 4 during maintenance. Four of the
9 chemotherapy-related deaths in the HR group were associated
with the high-dose blocks: 2 patients died in protocol I and
3 patients in protocol II (Table 4).
Relapses. CI at 6 years (6y-CI) of relapse was 16.2%
( 0.8%). Incidences within risk groups are shown in Table 4. BM
was the most frequent site of relapse in all risk groups. Six-year CI
of isolated CNS relapse and of all relapses with CNS involvement
was 1.8% ( 0.3%) and 4.1% ( 0.5%), respectively.
Secondary neoplasms. Thirty-four patients developed a SN at
a median time of 45.7 months (range, 8.7-105.1 months). Thirty of
them occurred after initial treatment in first CR. Among these,
acute myeloid leukemia (n 	 9) and myelodysplastic syndrome
(n 	 7) were most frequent. Two patients had an ALL; a relapse of
the primary ALL was ruled out in these cases. Other SN were
non-Hodgkin lymphoma (n 	 4), Hodgkin lymphoma (n 	 1),
PNET/Ewing sarcoma (n 	 2), malignant rhabdoid tumor (n 	 1),
malignant fibrous histiocytoma (n 	 1), Langerhans’ cell histiocy-
tosis (n 	 2), and granulocytic sarcoma (n 	 1). In 4 other patients,
the SN developed after relapse and relapse treatment: brain tumor
(n 	 2), Burkitt leukemia (n 	 1), and Epstein-Barr virus-
associated lymphoblastic lymphoma (n 	 1).
Evaluation of the new stratification strategy
The impact of the new risk stratification in ALL-BFM 95 was
evaluated in comparison to the former ALL-BFM 90 risk stratifica-
tion. Because HR criteria were basically the same in both trials, HR
patients were excluded from this analysis. EFS and resulting risk
ratios of the subgroups SR and MR by ALL-BFM 90 and
ALL-BFM 95 criteria are given in Table 5. Although both risk
stratifications resulted in significant differences between SR and
MR, discrimination was better when using ALL-BFM 95 criteria.
Impact of new or modified treatment elements
Dose reduction of anthracyclines in the SR group. To evaluate
the effect of the reduction of 2 doses of daunorubicin in protocol IA
in SR, data were compared with the matching historical control
group of ALL-BFM 9015 (see “Historical control group”). The
matching subset in ALL-BFM 90, which was SR by 95 criteria
(“SR-95”), had received a total of 4 doses of daunorubicin in
protocol IA.
The 6y-pEFS of SR patients in ALL-BFM 95 was 89.5%
( 1.1%; n 	 758) compared with 88.7% ( 1.1%; n 	 826) in
“SR-95” patients of ALL-BFM 90 (difference, 0.8%; 95% confi-
dence interval, 1.6% to 3.2%). Six-year CI of relapses was 7.8%
( 1.0%) in ALL-BFM 95 and 9.3% ( 1.0%) in “SR-95” patients
of ALL-BFM 90 (difference, 1.5%; 95% confidence interval,
1.3% to 5.5%). As approximately one-half each of the historical
control group was treated in risk group SR and MR, respectively,
the matching subgroups of the 2 trials were compared after
aditional subdivision into “SR-90” and “MR-90.” The results of
these analyses likewise showed no disadvantage of the daunorubi-
cin reduction in either subgroup (data not shown).
There were no cases of induction death in the ALL-BFM 95 SR
group, whereas 2 treatment-related deaths before CR occurred in
the “SR-95” group in ALL-BFM 90.
Extension of maintenance therapy in boys in the SR group.
Taking into account that the boys of the ALL-BFM 95 SR group
received 1 additional year of maintenance, further analyses of the
SR group were performed stratified by gender and once more
comparing the ALL-BFM 95 data with the matching subsets from
trial ALL-BFM 90. EFS of boys was similar in study ALL-BFM 90
(4 daunorubicin doses; 6y-pEFS, 87.5%  1.6%) and ALL-BFM
95 (2 daunorubicin doses  extended maintenance; 88.0%  1.6%,
P 	 .71; Figure 4). Likewise, no significant difference could be
shown comparing the outcome of girls in study ALL-BFM 90
(4 daunorubicin doses; 6y-pEFS, 90.0%  1.6%) to ALL-BFM 95
(2 daunorubicin doses; 6y-pEFS, 91.3%  1.6%, P 	 .79), who all
had received 24 months of maintenance therapy (Figure 4). In both
trials, there was a slightly worse pEFS in boys compared with girls
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Table 3. Patients’ characteristics
All patients (total n  2169)
Variable N* % 6y-pEFS, % (SE) SR, % (n  758) MR, % (n  1157) HR, % (n  254)
All 2169 100 79.6 (0.9) 100 100 100
Sex
Male 1226 56.5 78.4 (1.2) 54.9 56.4 61.8
Female 943 43.5 81.1 (1.3) 45.1 43.6 38.2
Age†
Less than 1 y 34 1.6 40.4 (8.5) 0 1.5 6.7
1 to less than 6 y 1255 57.9 84.3 (1.0) 100 35.1 35.8
6 to less than 10 y 447 20.6 80.3 (1.9) 0 33.1 25.2
10 to less than 15 y 340 15.7 70.5 (2.5) 0 23.9 25.2
15 y and older 93 4.3 58.3 (5.4) 0 6.5 7.1
Initial WBC (/ L)
Less than 10 000 1071 49.4 84.2 (1.1) 76.8 38.8 15.7
10 000 to less than 20  109/L 319 14.7 83.9 (2.1) 23.2 9.8 11.8
20 000 to less than 50  109/L 362 16.7 79.4 (2.2) 0 27.5 17.3
50 000 to less than 100  109/L 180 8.3 74.0 (3.3) 0 12.2 15.4
100 000 to less than 200  109/L 111 5.1 62.9 (4.6) 0 6.5 14.2
200 000 and over 126 5.8 52.6 (4.5) 0 5.3 25.6
BFM-RF
Less than 0.8 765 35.8 86.2 (1.3) 53.6 30.1 8.7
More than 0.8 1372 64.2 75.8 (1.2) 46.4 69.9 91.3
CNS status
CNS1 1717 79.5 81.3 (1.0) 84.7 77.9 71.0
CNS2 112 5.2 79.7 (3.9) 3.3 5.9 7.5
CNS3 64 3.0 57.7 (6.2) 1.2 2.9 8.7
TLP 148 6.8 69.2 (3.8) 4.1 8.2 9.1
TLP 119 5.5 81.0 (3.7) 6.7 5.1 3.6
Immunophenotype
Precursor B 1798 86.5 80.2 (1.0) 100 82.6 65.5
T 277 13.3 74.8 (2.6) 0 17.1 34.5
Other‡ 3 0.1 0 0.3 0
DNA index
Less than 1.16 1187 78.7 76.2 (1.3) 65.4 83.2 91.9
More than 1.16 322 21.3 88.9 (1.8) 34.6 16.8 8.1
TEL/AML1
Negative 916 78.6 75.1 (1.4) 73.2 78.7 94.4
Positive 250 21.4 91.2 (1.8) 26.8 21.3 5.6
BCR/ABL
Negative 1918 97.9 80.4 (0.9) 100 100 82.4
Positive 42 2.1 26.2 (6.8) 0 0 17.6
MLL/AF4
Negative 1154 97.9 77.4 (1.2) 100 100 86.9
Positive 25 2.1 40.0 (9.8) 0 0 13.1
Non-T lineage NCI risk criteria
Standard risk 1256 71.0 86.5 (1.0) 100 54.1 34.9
High risk 512 29.0 67.4 (2.1) 0 45.9 65.1
T lineage NCI risk criteria
Standard risk 72 26.2 90.1 (3.5) 33.3 10.5
High risk 203 73.8 69.2 (3.3) 66.7 89.5
Prednisone response
Good 1963 91.4 82.1 (0.9) 100 100 27.2
Poor 184 8.6 55.0 (3.7) 0 0 72.7
BM day 15
M1 880 61.5 87.1 (1.1) 72.2 65.0 22.3
M2 365 25.5 75.5 (2.3) 24.1 25.3 29.9
M3 186 13.0 47.3 (3.7) 3.8 9.7 47.7
Nonremission day 33
No 2120 97.7 80.6 (0.9) 100 100 80.7
Yes 49 2.3 36.3 (6.9) 0 0 19.3
CR indicates complete remission; BM, bone marrow; CNS, central nervous system; SR, standard risk; MR, medium risk; HR, high risk.
*Data refer to patients with successful investigation of the respective criteria.
†Median age was 5.0 years (range, 0.07-17.92 years). Nineteen additional patients younger than 1 year were treated in the Interfant-99 pilot study43 and were not included
in the analyses.
‡Two patients had the immunophenotype of a mature B-cell leukemia (cytomorphologically FAB L1); one patient had a biphenotypic acute leukemia.
NCI-SR, age 1 or younger and less than 10 years, and WBC less than 50109/L; NCI-HR, age 10 years or older or WBC 50109/Lor more. Infants less than 1 year are excluded from
the NCI definition.
¶One patient of the SR group was falsely BCR/ABL-negative at initial diagnosis (BCR/ABL-positive in relapse and in subsequently repeated analysis of the initial material).
TREATMENT OF CHILDHOOD ALL IN TRIAL ALL-BFM 95 4483BLOOD, 1 MAY 2008  VOLUME 111, NUMBER 9
 For personal use only. at UNIVERSITAETSSPITAL on February 9, 2009. www.bloodjournal.orgFrom 
(ALL-BFM 90, P 	 .049; ALL-BFM 95, P 	 .12). Six-year CI of
relapse was 9.0% ( 1.4%) in “SR-95” boys of ALL-BFM 95 and
11.3% ( 1.5%) in the matching boys in trial ALL-BFM 90
(P 	 .154).
Omission of preventive cranial radiotherapy in the MR group
and dose reduction of irradiation in patients with initial CNS
involvement
In study ALL-BFM 90, pCRT with 12 Gy was scheduled for all
“MR-90” patients. To evaluate the effect of the omission of pCRT
in all non-HR patients with pB-ALL in ALL-BFM 95, the
corresponding patient groups, which had an indication for pCRT in
trial ALL-BFM 90 but not in ALL-BFM 95, were compared. These
groups comprise patients aged 1 year or older with pB-ALL
without initial CNS involvement classified as “MR-90” according
to the ALL-BFM 90 risk criteria. The pEFS of these patients was
similar in ALL-BFM 90 (pCRT intended) and ALL-BFM 95 (pCRT
not intended; difference of pEFS at 6y, 1.6%, 95% confidence
interval, 4.4% to 1.1%; Figure 5A). Detailed analysis of relapse
sites revealed a significantly higher incidence of relapses with CNS
involvement in the nonirradiated patients in ALL-BFM 95 (6y-CI,
4.4%  0.8%) compared with the corresponding irradiated group
in ALL-BFM 90 (6y-CI, 1.9%  0.5%; P 	 .001), mostly because
of isolated CNS relapses (Figure 5B). Additional stratification by
“SR-95” and “MR-95” showed the same trend in either risk group,
whereas the incidence of isolated CNS relapses between ALL-
BFM 90 and 95 was similar in the remaining “MR-95” patients
who were SR by ALL-BFM 90 criteria and thus in neither trial were
irradiated (data not shown).
CNS3 patients aged one year or older in ALL-BFM 95, who
received tCRT with 18 Gy, showed no disadvantage in EFS
compared with CNS3 patients of trial ALL-BFM 90 who were
irradiated with 24 Gy (ALL-BFM 95, 59.2%  6.4%; ALL-BFM
90, 52.8%  7.3%; P 	 .63).
Intensification of protocol M by cytarabine in the MR group
Among the 1032 patients who were randomized to receive or not
additional cytarabine in protocol M, 518 patients were randomized
into protocol M and 514 into protocol MCA. In 9 patients,
randomized treatment was not applicable because of death (n 	 7)
or treatment withdrawal (n 	 2) after randomization but before
protocol M/MCA. Thirteen patients randomized to receive protocol
M and 69 patients randomized into protocol MCA were eventually
treated in the other arm. In 18 patients, the performed treatment
was not reported.
The intent-to-treat analysis revealed a 6y-pDFS of 80% ( 2%)
for protocol M and 80% ( 2%) for protocol MCA (P 	 .99). The
per-protocol analysis also showed no difference between the
treatment arms (6y-pDFS M, 80%  2%; MCA, 80%  2%;
P 	 .97). Deaths in CCR were similar in patients treated with
MCA (5 deaths) or M (3 deaths); none of them occurred concur-
rently with protocol M/MCA. Documentation of the individual
treatment schedule was available from 299 patients treated with M
and 233 patients with MCA. Patients receiving MCA needed a
median of 72 days (range, 53-139 days) to the subsequent treatment
element compared with 71 days (range, 60-119 days) in patients
receiving M.
Intensification of the HR treatment by modified high-dose
blocks and reinduction with protocol II
The modified treatment approach in ALL-BFM 95 was evaluated
compared with the HR treatment regimens of the previous trials
ALL-BFM 90 and ALL-BFM 86. To eliminate the bias by the
slightly different HR criteria of the 3 trials, only patients with PPR
and/or no CR on day 33 (NRd33) were compared. They were
eligible for HR treatment in all 3 trials and made up the majority of
the HR patients (84% of HR patients according to ALL-BFM 95
criteria). The results are shown in Figure 6. The inferior result of
the ALL-BFM 90 HR regimen compared with the HR treatment in
ALL-BFM 8615 could also be shown in the updated analysis for the
patients with PPR/NRd33 (P 	 .029). The HR treatment in ALL-
BFM 95 produced a 6y-pEFS of 53.2% ( 3.6%), which was
higher than in ALL-BFM 90 and 86 (Figure 6). The improved
outcome in the HR group of trial ALL-BFM 95 compared with
ALL-BFM 90 was due mainly to a lower incidence of nonresponse
(6y-CI ALL-BFM 90, 6.6%  1.7%; ALL-BFM 95, 2.0%  1.0%;
P 	 .020) and systemic relapses (6y-CI ALL-BFM 90,
51.3%  4.3%; ALL-BFM 95, 31.3%  3.9%; P 
 .001), whereas
the incidence of isolated extramedullary relapses was comparable
between the trials (6y-CI ALL-BFM 90, 3.5%  2.2%; ALL-BFM
95, 3.0%  1.7%; P 	 .76).
Figure 2. Kaplan-Meier estimate of event-free survival of all evaluable patients
in trials ALL-BFM 86, 90, and 95. Log-Rank tests: ALL-BFM 86 versus 90, P 	 .001;
ALL-BFM 86 versus 95, P 
 .001; ALL-BFM 90 versus 95, P 	 .062. 6y-pEFS
indicates probability of event-free survival at 6 years; SE, standard error.
Figure 3. Kaplan-Meier estimate of event-free survival of the trial ALL-BFM 95
according to risk groups. Log-rank test, P 
 .001. SR indicates standard risk; MR
medium risk; HR, high risk; 6y-pEFS, probability of event-free survival at 6 years; SE,
standard error.
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In patients with t(9;22) or BCR/ABL, the impact of the
modified ALL-BFM 95 HR treatment was only analyzed compared
with ALL-BFM 90 because t(9;22) was no HR criterion in the
earlier studies. No benefit from the ALL-BFM 95 HR treatment
could be proven in this patient subset; 6 year-pEFS was 33%
( 9%) in ALL-BFM 90 (n 	 27) compared with 26% ( 7%) in
ALL-BFM 95 (n 	 42; P 	 .91). In addition, for the patients with
t(4;11) or MLL/AF4, which per se was not a HR criterion in
ALL-BFM 90, pEFS could not be improved by the ALL-BFM 95
HR treatment (6y-pEFS ALL-BFM 90, 36%  10%, n 	 22;
ALL-BFM 95, 40%  10%; n 	 25; P 	 .55).
Treatment results in HR patients by additional alloSCT have
been published before.25,26
Discussion
The trial ALL-BFM 95 comprised a large unselected population of
2169 evaluable patients. Compared with the previous trial ALL-
BFM 90, results could be significantly improved in the HR group
through well-directed treatment intensification. On the other hand,
it was possible to maintain the excellent results of the former trial in
the large SR and MR subgroups despite significant dose reductions
with respect to anthracyclines in induction and cranial irradiation.
The randomized treatment intensifications in protocol M and
maintenance24 in the MR group were of no significant advantage.
Overall, ALL-BFM 95 showed a slight, not yet statistically
significant, improvement of 6y-pEFS compared with ALL-BFM 90
and an improved probability of survival.
For the newly defined SR group comprising approximately one-
third of all patients, an approximated pEFS of 90% was expected.
This gave reason to cautiously reduce the daunorubicin dose in this
Table 4. Treatment results
Risk group
All, n CI,* % (SE) SR, n CI,* % (SE) MR, n CI,* % (SE) HR, n CI,* % (SE)
Overall 2169 758 1157 254
Death before CR 16 0.7 (0.2) 0 13 1.1 (0.3) 3 1.2 (0.7)
Resistant disease 4 0.2 (0.1) 0 0 4 1.6 (0.8)
Death in first CR 46 2.1 (0.3) 5 0.7 (0.3) 19 1.6 (0.4) 22 8.7 (2.1)
During/after chemotherapy 33¶ 0.6 (0.2) 5 0.7 (0.3) 19 1.6 (0.4) 9 3.5 (1.2)
After stem cell transplantation† 13 1.5 (0.3) 0 0 13 5.1 (1.8)
Relapses 356 16.2 (0.8) 62 7.8 (1.0) 197 16.8 (1.2) 97 38.6 (3.6)
Isolated BM 232 10.5 (0.7) 41 5.1 (0.8) 120 10.1 (1.0) 71 28.3 (3.6)
Isolated CNS 39 1.8 (0.3) 8 1.1 (0.4) 25 2.2 (0.5) 6 2.4 (1.2)
Isolated testes 12 0.5 (0.2) 3 0.4 (0.3) 8 0.6 (0.3) 1 0.4 (0.7)
Combined CNS/BM involved 48 2.2 (0.4) 6 0.8 (0.3) 31 2.7 (0.5) 11 4.3 (1.7)
Combined BM/other (without CNS) 22 1.0 (0.2) 3 0.3 (0.2) 13 1.2 (0.4) 6 2.4 (1.5)
Other relapses‡ 3 0.1 (0.1) 1 0.1 (0.1) 0 2 0.8 (0.9)
Secondary neoplasms§ 30 2.0 (0.4) 17 2.4 (0.6) 11 1.8 (0.7) 2 2.1 (1.5)
CR indicates complete remission; BM, bone marrow; CNS, central nervous system; SR, standard risk; MR, medium risk; HR, high risk.
*Cumulative incidences are indicated at 6 years except for the secondary neoplasms, which are calculated at 10 years.
†A total of 58 patients underwent allogeneic stem cell transplantation in first CR.
‡Numbers of isolated mediastinal cases (1); isolated lumbosacral epidural (1); relapse site unknown (1; relapse diagnosed abroad).
§Four additional secondary neoplasms developed after relapse and relapse treatment.
Numbers of leukemia-associated cases: hypoxia resulting from mediastinal mass (1); cerebral bleeding (2); bacterial sepsis (1); multiple organ failure resulting from tumor
lysis syndrome (1); treatment-related: bacterial sepsis (6); cerebral bleeding (1); cerebral thrombosis (2); multiple organ failure (1); disseminated intravascular coagulation (1).
¶Number of cases of bacterial sepsis (8); fungal infection (9); viral infection (1); pneumocystis carinii pneumonia (1); infection/sepsis with unknown pathogen (7);
progressive leukencephalopathy (1); cerebral bleeding (2); cerebral infarction (1); interstitial pneumonia of unknown origin (2); and erroneous intrathecal vincristine application
(1).
Table 5. Impact of risk stratification according to ALL-BFM 90 and
ALL-BFM 95 risk criteria in non-HR patients of the 2 trials
(univariate Cox regression analysis)
N 6y-pEFS, % (SE)
Risk
ratio
95% confidence
interval P (Wald)
ALL-BFM 90
SR-90 635 85.4 (1.4) 1
MR-90 1285 81.7 (1.1) 1.40 1.11-1.77 .005
SR-95 826 88.7 (1.1) 1
MR-95 1094 78.7 (1.3) 1.99 1.59-2.49 
.001
ALL-BFM 95
SR-90 683 88.2 (1.3) 1
MR-90 1207 81.0 (1.1) 1.66 1.29-2.12 
.001
SR-95 758 89.5 (1.1) 1
MR-95 1157 79.7 (1.2) 2.05 1.60-2.63 
.001
Figure 4. Kaplan-Meier estimate of event-free survival and cumulative inci-
dence of relapses of SR patients by ALL-BFM 95 risk criteria (“SR-95”) in trials
ALL-BFM 90 and 95 according to sex. Patients of ALL-BFM 95 received 2 doses of
daunorubicin in induction, patients of ALL-BFM 90 4 doses. Duration of maintenance
was 36 months for boys of ALL-BFM 95 and 24 months for the remaining patients.
“SR-95” indicates standard risk by ALL-BFM 95 criteria; Ev, number of events; Rel,
number of relapses; 6y-pEFS, probability of event-free survival at 6 years; 6y-CI,
cumulative incidence of relapses at 6 years; SE, standard error.
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subset to diminish the risk of acute and late toxicity associated with
anthracyclines. Anthracycline-induced long-term cardiotoxicity has
been shown to be significantly associated with high cumulative
anthracycline doses.44-46 However, with longer follow-up, cardiac
abnormalities can also become obvious in patients treated with low
doses of less than 250 mg/m2.47,48 In the randomized trials, which
had been published at the time of the ALL-BFM 95 planning phase,
no benefit for the use of anthracyclines in addition to a 3-drug
induction with prednisone, vincristine, and L-asparaginase could
be proven with respect to EFS (for review, see Messinger et al49).
However, the treatment schedules in these trials were crucially
different from ALL-BFM 95, and results of these early trials were
inferior to the results in the BFM studies achieved at that time,
which hampered a clear extrapolation from those trials. In ALL-
BFM 90, the anthracycline dose in induction was already reduced
by 25% without adverse effects on survival, but this modification
was combined with a more condensed induction phase.15 Halving
the induction daunorubicin dose in the SR group in ALL-BFM 95
yielded an excellent 6y-pEFS of 89.5% and could be safely
performed as shown in comparison to the historical control group
of the previous trial ALL-BFM 90. This confirmed the prior results
of other trials and may encourage a further decrease of anthracy-
clines in ALL low-risk groups.
Boys have been shown to be at higher risk of relapse than girls,
particularly through a higher rate of late relapses after 2 years from
diagnosis.50-52 This observation was the rationale for the extension
of maintenance for boys in the ALL-BFM 95 SR group. Comparing
these patients with the matching subgroup of ALL-BFM 90, no
improvement of EFS could be achieved by the longer maintenance
treatment, although the data suggest a slight reduction of late
relapses (difference of point estimates at 10 years: P 	 .067).
However, it has to be pointed out that treatment of the matching
subgroups (“SR-95”) in ALL-BFM 90 and 95 in addition differed
in the number of daunorubicin doses in protocol I. This treatment
modification was not of disadvantage for “SR-95” girls, but an
interaction with the duration of maintenance in the male subset
cannot be fully excluded. A meta-analysis on the impact of duration
of maintenance performed by the Childhood ALL Collaborative
Group in 1996 revealed an overall slight benefit of a 3-year
maintenance duration compared with 2 years.53 However, the
results of the individual studies were not fully consistent,54-58
suggesting a variable impact in the context of different treatment
regimens. Furthermore, the overall effectiveness of the intensive
chemotherapy in those earlier trials is not necessarily comparable
with the studies conducted approximately 10 years later, and the
positive impact of longer maintenance may disappear with a more
effective intensive chemotherapy phase.
The omission of pCRT in all MR patients with pB-ALL in
ALL-BFM 95 affected approximately 50% of the total patient
population. The pCRT was omitted without replacement by intensi-
fied intrathecal or systemic chemotherapy. The association of
pCRT with secondary brain tumors as well as impairment of
endocrinologic and neurocognitive functions has frequently been
described in the literature.59-64 However, these trials refer to
irradiation doses of 18 Gy and higher, and little is known about the
impact of 12 Gy cranial irradiation with respect to CNS-related late
effects. The updated results from ALL-BFM 90 showed a CI of
brain tumors of 3.4% plus or minus 1.6% after 16 years among the
patients who had received 12 Gy pCRT demonstrating that even
Figure 5. Kaplan-Meier estimate and cumulative relapse incidences for evalua-
tion of the impact of preventive cranial radiotherapy. The curves compare the
matching patients from ALL-BFM 90 and 95 who received presymptomatic cranial
radiotherapy in trial ALL-BFM 90 yet were not irradiated in ALL-BFM 95 (pB-ALL,
aged 1 year or older, no initial CNS involvement, risk group MR-90). (A) Event-free
survival (P [log-rank] 	 .280). (B) Cumulative incidence of systemic relapses with
CNS involvement (P [Gray] 	 .270) and isolated CNS relapses (P [Gray] 
 .001).
Isol. CNS rel. indicates isolated relapse in the central nervous system; comb. CNS
rel., combined relapse involving the central nervous system; 6y-pEFS, probability of
event-free survival at 6 years; 6y-CI, cumulative incidence of relapses at 6 years; SE,
standard error.
Figure 6. Kaplan-Meier estimate of event-free survival of patients with pred-
nisone poor-response and/or nonremission on day 33 in the trials ALL-BFM 86,
90, and 95. All patients were treated in the HR arm of the respective trial. Log-rank
tests: ALL-BFM 86 versus 90, P 	 .029; ALL-BFM 86 versus 95, P 	 .14; ALL-BFM
90 versus 95, P 
 .001. 6y-pEFS indicates probability of event-free survival at 6
years; SE, standard error.
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with reduced doses secondary brain tumors still are a major
concern of pCRT. Because of the long latency of these events,
which in ALL-BFM 90 in median developed 9.8 years after
primary ALL diagnosis, a final statement regarding this issue
cannot yet be made for ALL-BFM 95. However, considering the
strong association between pCRT and the development of brain
tumors in ALL-BFM 90,60 it is likely that the incidence of brain
tumors will be reduced through omission of pCRT in pB-ALL MR
patients. There was a slightly yet significantly higher incidence of
isolated CNS relapses and a trend to more combined CNS relapses
in the nonirradiated patients from ALL-BFM 95 compared with the
matching patients of ALL-BFM 90. The increase of CNS relapses
with the omittance of pCRT either with or without replacement by
intensified intrathecal treatment has been reported before by
others.65-67 It is a dilemma to counterbalance the increase of (early
occurring) CNS relapses in the patients treated without pCRT
against the high incidence of secondary brain tumors after pCRT
developing typically after a long interval of several years. The
survival of the patients with brain tumor in ALL-BFM 90 was 0%
after 3.5 years with a median survival of 1.2 years. Survival of the
19 patients with isolated CNS relapse in the analyzed subgroup in
ALL-BFM 95 was 58% (SE 11%) at 6 years from relapse
diagnosis. Considering the dismal prognosis of the secondary
brain tumors and the other potential sequelae of CRT, we would
conclude that the moderate increase of the isolated CNS relapses
with favorable outcome in a considerable proportion of these
patients is worth to avoid the potential burden of pCRT and may
be overcome by treatment modifications, such as IT therapy in
the maintenance phase.
In the MR group, the combined administration of HD-MTX and
ID-cytarabine showed no advantage over HD-MTX alone. These
results are in accordance with 2 other randomized studies, which
tested the administration of ID-MTX or HD-MTX combined with
HD-cytarabine in consolidation and could also show no benefit
from additional cytarabine treatment.68,69 In these trials, the drugs
were administered simultaneously68 or overlapping starting the
cytarabine infusion at hour 12 of each ID-MTX infusion.69 In
contrast, a sequential regimen was conducted in ALL-BFM 95
starting ID-cytarabine at the end of the 24-hour HD-MTX infusion.
This was based on the results of in vitro studies demonstrating time
schedule-dependent antagonistic or synergistic effects of this drug
combination.70-72 However, the schedule of sequential administra-
tion as conducted in ALL-BFM 95 seems not to increase the
cytostatic effectiveness of HD-MTX in vivo. Patients receiving
MCA in median needed 1 more day to the subsequent element than
the control group. This difference was statistically significant
(P 	 .004) but, nevertheless, is rather unlikely to be clinically
relevant with respect to pEFS. However, it may reflect the higher
grade of hematologic toxicity and infections in protocol MCA
(Table S4).
In trial ALL-BFM 90, the HR treatment with 9 rotational
high-dose blocks yielded disappointing results, which were
worse than in the previous trial ALL-BFM 86. Major differences
between the HR treatments of the 2 trials comprised lower
individual and cumulative doses of alkylating agents and the
lack of a consolidation/reintensification element providing a
continuous drug exposure in trial ALL-BFM 90. Thus, the HR
treatment in ALL-BFM 95 was further modified mainly by
higher dose intensity of alkylating agents in the blocks and by
reintroduction of protocol II for late reintensification. This
treatment strategy led to a significant improvement of pEFS
compared with ALL-BFM 90 in patients with PPR and/or
NRd33. However, no improvement could be achieved for
patients with t(9;22). Despite the more intensive chemotherapy
regimen in the ALL-BFM 95 HR group, no increase of the
chemotherapy-related death rate was observed compared with
trial ALL-BFM 90 (6y-CI ALL-BFM 90, 3.7%  1.6%, ALL-
BFM 95 6y-CI, 3.5%  1.2%; P 	 .94). In addition, in other
study groups, intensification of therapy for poor-risk patients
have led to impressive improvements of outcome.21,66,73,74
However, the comparability with the ALL-BFM 95 HR therapy
is hampered by the variety of risk stratification strategies in
these trials leading to published results, which apply to distinct
patient subgroups. Trial AIEOP-ALL 95 used similar HR
stratification criteria as ALL-BFM 9574 enabling the comparison
of the 2 HR therapies. Four-year pEFS was 56.5% plus or minus
3.9% in AIEOP compared with 51.4% plus or minus 3.1% in
BFM; the only difference between the treatments was a second
protocol II in AIEOP-ALL 95 substituting the fourth to sixth HR
course of ALL-BFM 95. Whether the slightly better results in
AIEOP are the result of the differences in age distribution
(16.1% of the patients were  10 years in AIEOP vs 32.3% in
BFM) or to treatment differences is not fully known.
The SR and MR risk stratification in ALL-BFM 90 was based
mainly on the BFM-RF. With the aim to improve the discrimina-
tion between SR and MR and to allow an easier comparability
with the results of other trials, these criteria were modified in
ALL-BFM 95 substituting the BFM-RF by age and WBC. There
are basic similarities to the NCI consensus criteria, but catego-
ries were defined differently based on the cutoff points that
provided the best discrimination between risk groups in the
previous studies and to identify a SR group with an pEFS of
more than 90%. The new risk stratification resulted in an
extensive redistribution of non-HR patients. According to the
former risk criteria of ALL-BFM 90, 47% of the ALL-BFM 95
SR patients would have been treated in MR and 25% of MR
patients in SR. Applying the 2 stratification strategies of
ALL-BFM 90 and ALL-BFM 95 to the ALL-BFM 95 patient
population confirmed that the ALL-BFM 95 risk criteria ro-
bustly discriminate 3 different risk groups with better separation
compared with ALL-BFM 90 risk criteria.
Considerable progress could be achieved over the first
2 decades of running controlled treatment trials on childhood ALL.
However, the better the results, the more difficult it becomes to
achieve further significant improvement of the overall outcome. In
trial ALL-BFM 95, an excellent outcome of nearly 90% pEFS for
about one-third and 80% pEFS for about one-half of the total
childhood ALL population was achieved. Nevertheless, more than
70% of the events occurred in these subsets. Further efforts will be
necessary to establish sufficient methods to evaluate the individual
relapse risk and to allow specific risk-adapted treatment intensity
for all patients.
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